| Literature DB >> 27004256 |
Noboru Hanaoka1, Ryu Ishihara1, Noriya Uedo1, Yoji Takeuchi1, Koji Higashino1, Tomofumi Akasaka1, Takashi Kanesaka1, Noriko Matsuura1, Yasushi Yamasaki1, Kenta Hamada1, Hiroyasu Iishi1.
Abstract
BACKGROUND: Although steroid injection prevents stricture after esophageal endoscopic submucosal dissection (ESD), some patients require repeated sessions of endoscopic balloon dilation (EBD). We investigated the risk for refractory stricture despite the administration of steroid injections to prevent stricture in patients undergoing esophageal ESD. Refractory stricture was defined as the requirement for more than three sessions of EBD to resolve the stricture. In addition, the safety of steroid injections was assessed based on the rate of complications. PATIENTS AND METHODS: We analyzed data from 127 consecutive patients who underwent esophageal ESD and had mucosal defects with a circumferential extent greater than three-quarters of the esophagus. To prevent stricture, steroid injection was performed. EBD was performed whenever a patient had symptoms of dysphagia.Entities:
Year: 2016 PMID: 27004256 PMCID: PMC4798940 DOI: 10.1055/s-0042-100903
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1 aSuperficial Barrett’s cancer in the lower thoracic esophagus. Circumferential tumor extent ranges from 50 % to 75 %. b Marker dots are placed along the tumor margin. c Artificial ulcer after endoscopic submucosal dissection (ESD). d Triamcinolone is injected into the submucosal layer immediately after ESD. e No stricture has developed at 2 months after ESD.
Fig. 2 aSuperficial esophageal cancer in the upper thoracic esophagus. Circumferential tumor extent is greater than 75 %. b Semicircular dissection during endoscopic submucosal dissection (ESD). c Artificial ulcer after ESD. d Triamcinolone is injected into the submucosal layer immediately after ESD. e Stricture has developed at 2 months after ESD.
Characteristics of patients and lesions in a study of risk factors for esophageal stricture following endoscopic submucosal dissection.
| Refractory stricture | |||
| ( + ) (n = 24) | ( – ) (n = 103) |
| |
| Age, mean ± SD, y | 68 ± 8 | 67 ± 8 | 0.438 |
| Sex, male/female, n | 22/2 | 90/13 | 0.558 |
| Tumor location, n | 0.254 | ||
| Ce | 2 | 2 | |
| Ut, Mt, Lt | 21 | 98 | |
| EGJ | 1 | 3 | |
| Depth of invasion, n | 0.838 | ||
| T1a | 20 | 84 | |
| T1b | 4 | 19 | |
| Muscle exposure, n | 5 | 22 | 0.995 |
| History of radiation therapy, n | 1 | 7 | 0.633 |
| Tumor circumferential extent, n | 0.001 | ||
| > 1/2, ≤ 3/4 | 6 | 63 | |
| > 3/4 | 18 | 40 | |
| Tumor diameter, n | 0.561 | ||
| ≤ 40 mm | 5 | 21 | |
| ≤ 50 mm | 6 | 37 | |
| > 50 mm | 13 | 45 | |
SD, standard deviation; Ce, cervical esophagus; Ut, upper thoracic; Mt, middle thoracic; Lt, lower thoracic; EGJ, esophagogastric junction; EBD, endoscopic balloon dilation.
Predictors of risk for refractory stricture despite preventive steroid injection after endoscopic submucosal dissection.
| Tumor circumferential extent | Adjusted OR (95 % CI) |
|
| > 1/2, ≤ 3 /4 | Reference | |
| > 3/4 | 5.49 (1.91 – 15.84) | 0.002 |
OR, odds ratio; CI, confidence interval.
Adjusted for age, sex, history of radiation therapy, location of tumor, and tumor diameter.
Adverse events related to endoscopic balloon dilation.
| Case No. | Event | Age/sex | Tumor location | Depth of invasion | History of RT | Tumor circumferential extent | Tumor diameter, mm | EBDs before event, n |
| 1 | Perforation | 76/M | Lt | LP | No | > 1/2, ≤ 3/4 | 35 | 1 |
| 2 | Perforation | 69/M | Mt | LP | No | > 3/4 | 50 | 0 |
| 3 | Delayed perforation | 60/M | Mt | LP | No | > 3/4 | 50 | 0 |
RT, radiation therapy; EBD, endoscopic balloon dilation; Lt, lower thoracic; Mt, middle thoracic; LP, lamina propria.